References
- Breidbach A, Catlin DH, Green GA, Tregub I, Truong H, Gorzek J. Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin. Chem.49(6 Pt 1), 901–907 (2003).
- Dubois M, Fenaille F, Clement G et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal. Chem.80(5), 1737–1745 (2008).
- Guan F, Uboh CE, Soma LR et al. LC-MS/MS method for confirmation of recombinant human erythropoietin and darbepoetin a in equine plasma. Anal. Chem.79(12), 4627–4635 (2007).
- Bredehoft M, Schanzer W, Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun. Mass Spectrom.22(4), 477–485 (2008).
- Parker ML, Utiger RD, Ughaday WH. Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man. J. Clin. Invest.41, 262–268 (1962).
- Chung L, Clifford D, Buckley M, Baxter RC. Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J. Clin. Endocrinol. Metab.91(2), 671–677 (2006).
- Chung L, Baxter RC. Detection of growth hormone responsive proteins using SELDI-TOF mass spectrometry. Growth Horm. IGF Res.19(4), 383–387 (2009).
- Boateng J, Lancashire L, Brown P et al. The use of proteomic and bioinformatics techniques for the detection of protein biomarkers following growth hormone administration. Internet J. Genom. Proteomics2, 2 (2007).
- Ding J, List EO, Okada S, Kopchick JJ. Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm. IGF Res.19(4), 399–407 (2009).
- Aperghis M, Velloso CP, Hameed M et al. Serum IGF-I levels and IGF-I gene splicing in muscle of healthy young males receiving rhGH. Growth Horm. IGF Res.19(1), 61–67 (2008).
- Boateng J, Kay RG, Lancashire L et al. A proteomic approach combining MS and bioinformatic analysis for the detection and identification of biomarkers of administration of exogenous human growth hormone in humans. Proteomics Clin. Appl.3(8), 912–922 (2009).
- Kay RG, Barton C, Velloso C et al. High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich α-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun. Mass Spectrom.23, 3173–3182 (2009).
- Barton C, Beck P, Kay R, Teale P, Roberts J. Multiplexed LC-MS/MS analysis of horse plasma proteins to study doping in sport. Proteomics9(11), 3058–3065 (2009).
- Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics5(4), 573–588 (2006).
- Issaq HJ, Veenstra TD. Would you prefer multiple reaction monitoring or antibodies with your biomarker validation? Expert Rev. Proteomics5(6), 761–763 (2008).
- Kay RG, Gregory B, Grace PB, Pleasance S. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun. Mass Spectrom.21(16), 2585–2593 (2007).
- Kay RG, Barton C, Gentzer W, Vitzthum F, Pleasance S. Development of high-throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) assays for clinically relevant plasma proteins. J. Proteome Res.9(1), 333–340 (2009).
Website
- The WADA 2010 prohibited list www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/WADA_Prohibited_List_2010_EN.pdf